The coxibs are a subclass of nonsteroidal antiinflammatory drugs(NSAIDs) designed to inhibit selectively cyclooxygenase-2 (COX-2).1Their development was based on the hypothesis that COX-2 wasthe source of prostaglandins E2 and I2, which mediate inflammation,and that cyclooxygenase-1 (COX-1) was the source of the sameprostaglandins in gastric epithelium, where they afford cytoprotection.Three coxibs — celecoxib, rofecoxib, and valdecoxib —have been approved for use by the Food and Drug Administration(FDA); a fourth, etoricoxib, has been approved by the Europeanregulatory authority, and it and a fifth, lumiracoxib, are currentlyunder consideration for FDA approval.
Ansari, K. M., Rundhaug, J. E., Fischer, S. M.
(2008). Multiple Signaling Pathways Are Responsible for Prostaglandin E2-Induced Murine Keratinocyte Proliferation. Mol Cancer Res
6: 1003-1016
[Abstract][Full Text]
Patrono, C., Baigent, C., Hirsh, J., Roth, G.
(2008). Antiplatelet Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest
133: 199S-233S
[Abstract][Full Text]
Panoulas, V. F., Metsios, G. S., Pace, A. V., John, H., Treharne, G. J., Banks, M. J., Kitas, G. D.
(2008). Hypertension in rheumatoid arthritis. Rheumatology (Oxford)
0: ken159v2-ken159
[Abstract][Full Text]
Clark, P., Rowland, S. E., Denis, D., Mathieu, M.-C., Stocco, R., Poirier, H., Burch, J., Han, Y., Audoly, L., Therien, A. G., Xu, D.
(2008). MF498 [N-{[4-(5,9-Diethoxy-6-oxo-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl)-3-methylbenzyl]sulfonyl}-2-(2-methoxyphenyl)acetamide], a Selective E Prostanoid Receptor 4 Antagonist, Relieves Joint Inflammation and Pain in Rodent Models of Rheumatoid and Osteoarthritis. J. Pharmacol. Exp. Ther.
325: 425-434
[Abstract][Full Text]
Arehart, E., Stitham, J., Asselbergs, F. W., Douville, K., MacKenzie, T., Fetalvero, K. M., Gleim, S., Kasza, Z., Rao, Y., Martel, L., Segel, S., Robb, J., Kaplan, A., Simons, M., Powell, R. J., Moore, J. H., Rimm, E. B., Martin, K. A., Hwa, J.
(2008). Acceleration of Cardiovascular Disease by a Dysfunctional Prostacyclin Receptor Mutation: Potential Implications for Cyclooxygenase-2 Inhibition. Circ. Res.
102: 986-993
[Abstract][Full Text]
Solomon, S. D., Wittes, J., Finn, P. V., Fowler, R., Viner, J., Bertagnolli, M. M., Arber, N., Levin, B., Meinert, C. L., Martin, B., Pater, J. L., Goss, P. E., Lance, P., Obara, S., Chew, E. Y., Kim, J., Arndt, G., Hawk, E., for the Cross Trial Safety Assessment Group,
(2008). Cardiovascular Risk of Celecoxib in 6 Randomized Placebo-Controlled Trials: The Cross Trial Safety Analysis. Circulation
117: 2104-2113
[Abstract][Full Text]
Taketa, K., Matsumura, T., Yano, M., Ishii, N., Senokuchi, T., Motoshima, H., Murata, Y., Kim-Mitsuyama, S., Kawada, T., Itabe, H., Takeya, M., Nishikawa, T., Tsuruzoe, K., Araki, E.
(2008). Oxidized Low Density Lipoprotein Activates Peroxisome Proliferator-activated Receptor-{alpha} (PPAR{alpha}) and PPAR{gamma} through MAPK-dependent COX-2 Expression in Macrophages. J. Biol. Chem.
283: 9852-9862
[Abstract][Full Text]
Subbaramaiah, K., Hudis, C., Chang, S.-H., Hla, T., Dannenberg, A. J.
(2008). EP2 and EP4 Receptors Regulate Aromatase Expression in Human Adipocytes and Breast Cancer Cells: EVIDENCE OF A BRCA1 AND p300 EXCHANGE. J. Biol. Chem.
283: 3433-3444
[Abstract][Full Text]
Kardosh, A., Golden, E. B., Pyrko, P., Uddin, J., Hofman, F. M., Chen, T. C., Louie, S. G., Petasis, N. A., Schonthal, A. H.
(2008). Aggravated Endoplasmic Reticulum Stress as a Basis for Enhanced Glioblastoma Cell Killing by Bortezomib in Combination with Celecoxib or Its Non-Coxib Analogue, 2,5-Dimethyl-Celecoxib. Cancer Res.
68: 843-851
[Abstract][Full Text]
Frolov, R. V., Berim, I. G., Singh, S.
(2008). Inhibition of Delayed Rectifier Potassium Channels and Induction of Arrhythmia: A NOVEL EFFECT OF CELECOXIB AND THE MECHANISM UNDERLYING IT. J. Biol. Chem.
283: 1518-1524
[Abstract][Full Text]
Joshi, G. P., Gertler, R., Fricker, R.
(2007). Cardiovascular Thromboembolic Adverse Effects Associated with Cyclooxygenase-2 Selective Inhibitors and Nonselective Antiinflammatory Drugs. Anesth. Analg.
105: 1793-1804
[Abstract][Full Text]
Letts, G., Loscalzo, J.
(2007). Frontiers in Nephrology: Targeting Inflammation Using Novel Nitric Oxide Donors. J. Am. Soc. Nephrol.
18: 2863-2869
[Abstract][Full Text]
Frye, R. L.
(2007). Update in Cardiology. ANN INTERN MED
147: 180-186
[Full Text]
Mosca, M., Polentarutti, N., Mangano, G., Apicella, C., Doni, A., Mancini, F., De Bortoli, M., Coletta, I., Polenzani, L., Santoni, G., Sironi, M., Vecchi, A., Mantovani, A.
(2007). Regulation of the microsomal prostaglandin E synthase-1 in polarized mononuclear phagocytes and its constitutive expression in neutrophils. J. Leukoc. Biol.
82: 320-326
[Abstract][Full Text]
Klein, T., Eltze, M., Grebe, T., Hatzelmann, A., Komhoff, M.
(2007). Celecoxib dilates guinea-pig coronaries and rat aortic rings and amplifies NO/cGMP signaling by PDE5 inhibition. Cardiovasc Res
75: 390-397
[Abstract][Full Text]
Habib, A., Shamseddeen, I., Nasrallah, M. S., Antoun, T. A., Nemer, G., Bertoglio, J., Badreddine, R., Badr, K. F.
(2007). Modulation of COX-2 expression by statins in human monocytic cells. FASEB J.
21: 1665-1674
[Abstract][Full Text]
Pyrko, P., Kardosh, A., Liu, Y.-T., Soriano, N., Xiong, W., Chow, R. H., Uddin, J., Petasis, N. A., Mircheff, A. K., Farley, R. A., Louie, S. G., Chen, T. C., Schonthal, A. H.
(2007). Calcium-activated endoplasmic reticulum stress as a major component of tumor cell death induced by 2,5-dimethyl-celecoxib, a non-coxib analogue of celecoxib. Molecular Cancer Therapeutics
6: 1262-1275
[Abstract][Full Text]
Antman, E. M., Bennett, J. S., Daugherty, A., Furberg, C., Roberts, H., Taubert, K. A.
(2007). Use of Nonsteroidal Antiinflammatory Drugs: An Update for Clinicians: A Scientific Statement From the American Heart Association. Circulation
115: 1634-1642
[Full Text]
Gross, S., Tilly, P., Hentsch, D., Vonesch, J.-L., Fabre, J.-E.
(2007). Vascular wall-produced prostaglandin E2 exacerbates arterial thrombosis and atherothrombosis through platelet EP3 receptors. J. Exp. Med.
204: 311-320
[Abstract][Full Text]
Yu, Y., Fan, J., Hui, Y., Rouzer, C. A., Marnett, L. J., Klein-Szanto, A. J., FitzGerald, G. A., Funk, C. D.
(2007). Targeted Cyclooxygenase Gene (Ptgs) Exchange Reveals Discriminant Isoform Functionality. J. Biol. Chem.
282: 1498-1506
[Abstract][Full Text]
Gitlin, J. M., Trivedi, D. B., Langenbach, R., Loftin, C. D.
(2007). Genetic deficiency of cyclooxygenase-2 attenuates abdominal aortic aneurysm formation in mice. Cardiovasc Res
73: 227-236
[Abstract][Full Text]
Anning, P. B., Coles, B., Morton, J., Wang, H., Uddin, J., Morrow, J. D., Dey, S. K., Marnett, L. J., O'Donnell, V. B.
(2006). Nitric oxide deficiency promotes vascular side effects of cyclooxygenase inhibitors. Blood
108: 4059-4062
[Abstract][Full Text]
Stitham, J., Gleim, S. R., Douville, K., Arehart, E., Hwa, J.
(2006). Versatility and Differential Roles of Cysteine Residues in Human Prostacyclin Receptor Structure and Function. J. Biol. Chem.
281: 37227-37236
[Abstract][Full Text]
Jia, Z., Zhang, A., Zhang, H., Dong, Z., Yang, T.
(2006). Deletion of Microsomal Prostaglandin E Synthase-1 Increases Sensitivity to Salt Loading and Angiotensin II Infusion. Circ. Res.
99: 1243-1251
[Abstract][Full Text]
Massaro, M., Habib, A., Lubrano, L., Turco, S. D., Lazzerini, G., Bourcier, T., Weksler, B. B., De Caterina, R.
(2006). The omega-3 fatty acid docosahexaenoate attenuates endothelial cyclooxygenase-2 induction through both NADP(H) oxidase and PKC{varepsilon} inhibition. Proc. Natl. Acad. Sci. USA
103: 15184-15189
[Abstract][Full Text]
Yang, L., Huang, Y., Porta, R., Yanagisawa, K., Gonzalez, A., Segi, E., Johnson, D. H., Narumiya, S., Carbone, D. P.
(2006). Host and Direct Antitumor Effects and Profound Reduction in Tumor Metastasis with Selective EP4 Receptor Antagonism. Cancer Res.
66: 9665-9672
[Abstract][Full Text]
Schmelzer, K. R., Inceoglu, B., Kubala, L., Kim, I.-H., Jinks, S. L., Eiserich, J. P., Hammock, B. D.
(2006). Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors. Proc. Natl. Acad. Sci. USA
103: 13646-13651
[Abstract][Full Text]
Wang, H.-W., Hsueh, C.-T., Lin, C.-F. J., Chou, T.-Y., Hsu, W.-H., Wang, L.-S., Wu, Y.-C.
(2006). Clinical Implications of Microsomal Prostaglandin E Synthase-1 Overexpression in Human Non-Small-Cell Lung Cancer. Ann. Surg. Oncol.
13: 1224-1234
[Abstract][Full Text]
Szerafin, T., Erdei, N., Fulop, T., Pasztor, E. T., Edes, I., Koller, A., Bagi, Z.
(2006). Increased Cyclooxygenase-2 Expression and Prostaglandin-Mediated Dilation in Coronary Arterioles of Patients With Diabetes Mellitus. Circ. Res.
99: e12-317
[Abstract][Full Text]
Lovgren, A. K., Jania, L. A., Hartney, J. M., Parsons, K. K., Audoly, L. P., FitzGerald, G. A., Tilley, S. L., Koller, B. H.
(2006). COX-2-derived prostacyclin protects against bleomycin-induced pulmonary fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol.
291: L144-L156
[Abstract][Full Text]
Traynor, B. J., Bruijn, L., Conwit, R., Beal, F., O'Neill, G., Fagan, S. C., Cudkowicz, M. E.
(2006). Neuroprotective agents for clinical trials in ALS: A systematic assessment.. Neurology
67: 20-27
[Abstract][Full Text]
Komhoff, M., Klaus, G., Nazarowa, S., Reinalter, S. C., Seyberth, H. W.
(2006). Increased systolic blood pressure with rofecoxib in congenital furosemide-like salt loss. Nephrol Dial Transplant
21: 1833-1837
[Abstract][Full Text]
Roca-Ferrer, J, Pujols, L, Gartner, S, Moreno, A, Pumarola, F, Mullol, J, Cobos, N, Picado, C
(2006). Upregulation of COX-1 and COX-2 in nasal polyps in cystic fibrosis. Thorax
61: 592-596
[Abstract][Full Text]
Andersohn, F., Schade, R., Suissa, S., Garbe, E.
(2006). Cyclooxygenase-2 Selective Nonsteroidal Anti-Inflammatory Drugs and the Risk of Ischemic Stroke: A Nested Case-Control Study. Stroke
37: 1725-1730
[Abstract][Full Text]
Carothers, A. M., Moran, A. E., Cho, N. L., Redston, M., Bertagnolli, M. M.
(2006). Changes in Antitumor Response in C57BL/6J-Min/+ Mice during Long-term Administration of a Selective Cyclooxygenase-2 Inhibitor.. Cancer Res.
66: 6432-6438
[Abstract][Full Text]
Grosch, S., Maier, T. J., Schiffmann, S., Geisslinger, G.
(2006). Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors.. JNCI J Natl Cancer Inst
98: 736-747
[Abstract][Full Text]
Authors/Task Force Members, , Fox, K., Garcia, M. A. A., Ardissino, D., Buszman, P., Camici, P. G., Crea, F., Daly, C., De Backer, G., Hjemdahl, P., Lopez-Sendon, J., Marco, J., Morais, J., Pepper, J., Sechtem, U., Simoons, M., Thygesen, K., ESC Committee for Practice Guidelines (CPG), , Priori, S. G., Blanc, J.-J., Budaj, A., Camm, J., Dean, V., Deckers, J., Dickstein, K., Lekakis, J., McGregor, K., Metra, M., Morais, J., Osterspey, A., Tamargo, J., Zamorano, J. L., Document Reviewers, , Zamorano, J. L, Andreotti, F., Becher, H., Dietz, R., Fraser, A., Gray, H., Antolin, R. A. H., Huber, K., Kremastinos, D. T., Maseri, A., Nesser, H.-J., Pasierski, T., Sigwart, U., Tubaro, M., Weis, M.
(2006). Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J
27: 1341-1381
[Full Text]
Andersohn, F., Suissa, S., Garbe, E.
(2006). Use of First- and Second-Generation Cyclooxygenase-2-Selective Nonsteroidal Antiinflammatory Drugs and Risk of Acute Myocardial Infarction. Circulation
113: 1950-1957
[Abstract][Full Text]
Wong, P.-S., Asmat, A., Chan, Y.-H., Lee, C.-N.
(2006). A randomized, double-blind, placebo-controlled trial of a COX-2 inhibitor (Rofecoxib) in patients undergoing coronary artery bypass surgery. ICVTS
5: 101-104
[Abstract][Full Text]
Miller, B., Patel, V. A., Sorokin, A.
(2006). Cyclooxygenase-2 Rescues Rat Mesangial Cells from Apoptosis Induced by Adriamycin via Upregulation of Multidrug Resistance Protein 1 (P-Glycoprotein). J. Am. Soc. Nephrol.
17: 977-985
[Abstract][Full Text]
Sooriakumaran, P
(2006). COX-2 inhibitors and the heart: are all coxibs the same?. Postgrad. Med. J.
82: 242-245
[Abstract][Full Text]
Caldwell, B., Aldington, S., Weatherall, M., Shirtcliffe, P., Beasley, R.
(2006). Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis.. JRSM
99: 132-140
[Abstract][Full Text]
Blankfield, R. P.
(2006). Can Natriuretic Peptide Levels Predict the Cardiovascular Complications of COX-2 Inhibitors and Nonsteroidal Anti-inflammatory Drugs?. J Am Board Fam Med
19: 178-182
[Abstract][Full Text]
Ridley, D. B., Kramer, J. M., Tilson, H. H., Grabowski, H. G., Schulman, K. A.
(2006). Spending on postapproval drug safety.. Health Aff (Millwood)
25: 429-436
[Abstract][Full Text]
Harris, R. C., Breyer, M. D.
(2006). Update on Cyclooxygenase-2 Inhibitors. CJASN
1: 236-245
[Abstract][Full Text]
Felson, D. T.
(2006). Clinical practice. Osteoarthritis of the knee.. NEJM
354: 841-848
[Full Text]
Honda, T., Segi-Nishida, E., Miyachi, Y., Narumiya, S.
(2006). Prostacyclin-IP signaling and prostaglandin E2-EP2/EP4 signaling both mediate joint inflammation in mouse collagen-induced arthritis. J. Exp. Med.
203: 325-335
[Abstract][Full Text]
Romundstad, L., Breivik, H., Roald, H., Skolleborg, K., Haugen, T., Narum, J., Stubhaug, A.
(2006). Methylprednisolone Reduces Pain, Emesis, and Fatigue After Breast Augmentation Surgery: A Single-Dose, Randomized, Parallel-Group Study with Methylprednisolone 125 mg, Parecoxib 40 mg, and Placebo. Anesth. Analg.
102: 418-425
[Abstract][Full Text]
van den Boom, M., Sarbia, M., von Wnuck Lipinski, K., Mann, P., Meyer-Kirchrath, J., Rauch, B.H., Grabitz, K., Levkau, B., Schror, K., Fischer, J.W.
(2006). Differential Regulation of Hyaluronic Acid Synthase Isoforms in Human Saphenous Vein Smooth Muscle Cells: Possible Implications for Vein Graft Stenosis. Circ. Res.
98: 36-44
[Abstract][Full Text]
Babaev, V. R., Ding, L., Reese, J., Morrow, J. D., Breyer, M. D., Dey, S. K., Fazio, S., Linton, M. F.
(2006). Cyclooxygenase-1 Deficiency in Bone Marrow Cells Increases Early Atherosclerosis in Apolipoprotein E- and Low-Density Lipoprotein Receptor-Null Mice. Circulation
113: 108-117
[Abstract][Full Text]
Bolten, W W
(2006). Problem of the atherothrombotic potential of non-steroidal anti-inflammatory drugs. Ann Rheum Dis
65: 7-13
[Abstract][Full Text]
Hall, F. C., Dalbeth, N.
(2005). Disease modification and cardiovascular risk reduction: two sides of the same coin?. Rheumatology (Oxford)
44: 1473-1482
[Abstract][Full Text]
Cui, W., Yu, C.-H., Hu, K.-Q.
(2005). In vitro and In vivo Effects and Mechanisms of Celecoxib-Induced Growth Inhibition of Human Hepatocellular Carcinoma Cells. Clin. Cancer Res.
11: 8213-8221
[Abstract][Full Text]
Chang, T.-C., Huang, C.-J., Tam, K., Chen, S.-F., Tan, K. T., Tsai, M.-S., Lin, T.-N., Shyue, S.-K.
(2005). Stabilization of Hypoxia-inducible Factor-1{alpha} by Prostacyclin under Prolonged Hypoxia via Reducing Reactive Oxygen Species Level in Endothelial Cells. J. Biol. Chem.
280: 36567-36574
[Abstract][Full Text]
Fosslien, E.
(2005). Cardiovascular Complications of Non-Steroidal Anti-Inflammatory Drugs. Annals of Clinical & Laboratory Science
35: 347-385
[Abstract][Full Text]
Csiki, I., Morrow, J. D., Sandler, A., Shyr, Y., Oates, J., Williams, M. K., Dang, T., Carbone, D. P., Johnson, D. H.
(2005). Targeting Cyclooxygenase-2 in Recurrent Non-Small Cell Lung Cancer: A Phase II Trial of Celecoxib and Docetaxel. Clin. Cancer Res.
11: 6634-6640
[Abstract][Full Text]
Genuis, S. J.
(2005). The Proliferation of Clinical Practice Guidelines: Professional Development or Medicine-by-Numbers?. J Am Board Fam Med
18: 419-425
[Abstract][Full Text]
Choe, M. S., Zhang, X., Shin, H. J. C., Shin, D. M., Chen, Z.
(2005). Interaction between epidermal growth factor receptor- and cyclooxygenase 2-mediated pathways and its implications for the chemoprevention of head and neck cancer. Molecular Cancer Therapeutics
4: 1448-1455
[Abstract][Full Text]
Cipollone, F., Fazia, M. L., Iezzi, A., Cuccurullo, C., De Cesare, D., Ucchino, S., Spigonardo, F., Marchetti, A., Buttitta, F., Paloscia, L., Mascellanti, M., Cuccurullo, F., Mezzetti, A.
(2005). Association Between Prostaglandin E Receptor Subtype EP4 Overexpression and Unstable Phenotype in Atherosclerotic Plaques in Human. Arterioscler. Thromb. Vasc. Bio.
25: 1925-1931
[Abstract][Full Text]
Pratico, D., Dogne, J.-M.
(2005). Selective Cyclooxygenase-2 Inhibitors Development in Cardiovascular Medicine. Circulation
112: 1073-1079
[Full Text]
Rigas, B., Kashfi, K.
(2005). Cancer Prevention: A New Era beyond Cyclooxygenase-2. J. Pharmacol. Exp. Ther.
314: 1-8
[Abstract][Full Text]
Gottlieb, S.
(2005). Opening Pandora's Pillbox: Using Modern Information Tools To Improve Drug Safety. Health Aff (Millwood)
24: 938-948
[Abstract][Full Text]
Konstantinopoulos, P. A., Lehmann, D. F.
(2005). The Cardiovascular Toxicity of Selective and Nonselective Cyclooxygenase Inhibitors: Comparisons, Contrasts, and Aspirin Confounding. J Clin Pharmacol
45: 742-750
[Abstract][Full Text]
Jones, S C.
(2005). Relative Thromboembolic Risks Associated with COX-2 Inhibitors. The Annals of Pharmacotherapy
39: 1249-1259
[Abstract][Full Text]
Rudic, R. D., Brinster, D., Cheng, Y., Fries, S., Song, W.-L., Austin, S., Coffman, T. M., FitzGerald, G. A.
(2005). COX-2-Derived Prostacyclin Modulates Vascular Remodeling. Circ. Res.
96: 1240-1247
[Abstract][Full Text]
Hudson, M., Richard, H., Pilote, L.
(2005). Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study. BMJ
330: 1370-
[Abstract][Full Text]
Virchow, J. C.
(2005). Fluticasone Reduces CRP in COPD. Am. J. Respir. Crit. Care Med.
171: 1191-1191
[Full Text]
Winters, M. E., Mehta, A. I., Petricoin, E. F. III, Kohn, E. C., Liotta, L. A.
(2005). Supra-additive Growth Inhibition by a Celecoxib Analogue and Carboxyamido-triazole Is Primarily Mediated through Apoptosis. Cancer Res.
65: 3853-3860
[Abstract][Full Text]
Montine, T. J., Morrow, J. D.
(2005). Fatty Acid Oxidation in the Pathogenesis of Alzheimer's Disease. Am. J. Pathol.
166: 1283-1289
[Abstract][Full Text]
Fredy, J., Diggins, D. A Jr, Morrill, G. B
(2005). Blood Pressure in Native Americans Switched from Celecoxib to Rofecoxib. The Annals of Pharmacotherapy
39: 797-802
[Abstract][Full Text]
Juhaszova, M., Rabuel, C., Zorov, D. B., Lakatta, E. G., Sollott, S. J.
(2005). Protection in the aged heart: preventing the heart-break of old age?. Cardiovasc Res
66: 233-244
[Abstract][Full Text]
Bernatsky, S., Hudson, M., Suissa, S.
(2005). Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis. Rheumatology (Oxford)
44: 677-680
[Abstract][Full Text]
Bennett, J. S., Daugherty, A., Herrington, D., Greenland, P., Roberts, H., Taubert, K. A.
(2005). The Use of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): A Science Advisory From the American Heart Association. Circulation
111: 1713-1716
[Full Text]
Schror, K., Mehta, P., Mehta, J. L.
(2005). Cardiovascular Risk of Selective Cyclooxygenase-2 Inhibitors. J CARDIOVASC PHARMACOL THER
10: 95-101
[Abstract]
Wu, K. K., Liou, J.-Y., Cieslik, K.
(2005). Transcriptional Control of COX-2 via C/EBP{beta}. Arterioscler. Thromb. Vasc. Bio.
25: 679-685
[Abstract][Full Text]
Solomon, S. D., McMurray, J. J.V., Pfeffer, M. A., Wittes, J., Fowler, R., Finn, P., Anderson, W. F., Zauber, A., Hawk, E., Bertagnolli, M., the Adenoma Prevention with Celecoxib (APC) Study,
(2005). Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention. NEJM
352: 1071-1080
[Abstract][Full Text]
Nussmeier, N. A., Whelton, A. A., Brown, M. T., Langford, R. M., Hoeft, A., Parlow, J. L., Boyce, S. W., Verburg, K. M.
(2005). Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac Surgery. NEJM
352: 1081-1091
[Abstract][Full Text]
Alberts, D. S., Potter, J. D., Martinez, M. E., Hess, L. M., Stopeck, A., Lance, P.
(2005). What Happened to the Coxibs on the Way to the Cardiologist?. Cancer Epidemiol. Biomarkers Prev.
14: 555-556
[Full Text]
Bhattacharyya, T., Smith, R. M.
(2005). Cardiovascular Risks of Coxibs: The Orthopaedic Perspective. JBJS
87: 245-246
[Full Text]
Pini, B., Grosser, T., Lawson, J. A., Price, T. S., Pack, M. A., FitzGerald, G. A.
(2005). Prostaglandin E Synthases in Zebrafish. Arterioscler. Thromb. Vasc. Bio.
25: 315-320
[Abstract][Full Text]
Iadecola, C., Gorelick, P. B.
(2005). The Janus Face of Cyclooxygenase-2 in Ischemic Stroke: Shifting Toward Downstream Targets. Stroke
36: 182-185
[Full Text]
Chang, I. J., Harris, R. C.
(2005). Are All COX-2 Inhibitors Created Equal?. Hypertension
45: 178-180
[Full Text]
Roden, D. M.
(2005). An Underrecognized Challenge in Evaluating Postmarketing Drug Safety. Circulation
111: 246-248
[Full Text]
Egan, K. M., Wang, M., Lucitt, M. B., Zukas, A. M., Pure, E., Lawson, J. A., FitzGerald, G. A.
(2005). Cyclooxygenases, Thromboxane, and Atherosclerosis: Plaque Destabilization by Cyclooxygenase-2 Inhibition Combined With Thromboxane Receptor Antagonism. Circulation
111: 334-342
[Abstract][Full Text]
Rabausch, K., Bretschneider, E., Sarbia, M., Meyer-Kirchrath, J., Censarek, P., Pape, R., Fischer, J. W., Schror, K., Weber, A.-A.
(2005). Regulation of Thrombomodulin Expression in Human Vascular Smooth Muscle Cells by COX-2-Derived Prostaglandins. Circ. Res.
96: e1-e6
[Abstract][Full Text]
Chua, S.S., Paraidathathu, T.
(2005). Utilisation of Non-steroidal Anti-inflammatory Drugs (NSAIDs) through Community Pharmacies in Malaysia. Asia Pac J Public Health
17: 117-123
[Abstract]
Hassan, A. A., Kroll, M. H.
(2005). Acquired Disorders of Platelet Function. ASH Education Book
2005: 403-408
[Abstract][Full Text]
Kim, P. S., Reicin, A. S., Villalba, L., Witter, J., Wolfe, M. M., Topol, E. J.
(2004). Rofecoxib, Merck, and the FDA. NEJM
351: 2875-2878
[Full Text]
(2004). The Next Chapter in the COX-2 Saga. Journal Watch Cardiology
2004: 2-2
[Full Text]
(2004). Perspective on the Vioxx Recall. JWatch General
2004: 1-1
[Full Text]
Previous
